Lung Cancer
FDA grants orphan drug designation to serplulimab for small cell lung cancer
The FDA granted orphan drug designation to serplulimab for treatment of small cell lung cancer.
AI model may predict adverse events of combination therapies for various cancer types
An artificial intelligence model appeared to predict adverse events associated with novel combination therapies for various cancer types, according to study results presented at American Association for Cancer Research Annual Meeting.
Neoadjuvant nivolumab plus chemotherapy extends EFS in non-small cell lung cancer
Neoadjuvant nivolumab plus chemotherapy significantly improved EFS in stage IB to stage IIIA resectable non-small cell lung cancer, according to research presented at American Association for Cancer Research Annual Meeting.
Patients with non-small lung cancer with CTLA-4 variant may respond better to immunotherapy
Patients with non-small cell lung cancer and an exceptionally high anti-PD-1 therapy response more frequently had a variant of the CTLA-4 gene, which may be used to identify those who may benefit from such treatment.
Sotorasib confers durable benefit in lung cancer subset
Sotorasib exhibited durable efficacy among certain adults with locally advanced or metastatic non-small cell lung cancer, according to study results presented at American Association for Cancer Research Annual Meeting.
Tobacco cessation program empowers patients at ‘teachable moment’ before cancer surgery
Although smoking cessation is known to benefit patients with cancer, obstacles exist at the patient, clinician and institutional levels, according to a poster presentation at American Association for Cancer Research Annual Meeting.
Patient-reported outcomes linked to nonfatal self-injury after cancer diagnosis
Self-reported signs of distress and an increasing total Edmonton Symptom Assessment System score within 180 days of cancer diagnosis appeared associated with higher odds of nonfatal, self-inflicted injury, study results showed.
Lung cancer screening less common among those most likely to benefit from it
Individuals whose underlying poor health may make them less likely to benefit from lung cancer screening appeared more likely to undergo the scans than those with better health status, according to study results in JAMA Network Open.
Blood-based microRNA signature may predict survival in immunotherapy-treated NSCLC
A blood-based signature of five microRNAs demonstrated the ability to predict OS of patients with lung cancer receiving immunotherapy and stratify them for treatment, according to a study published in npj Precision Oncology.
Phase 3 trial of regimen for small cell lung cancer misses co-primary endpoint
A randomized phase 3 trial designed to assess the addition of tiragolumab to atezolizumab and chemotherapy for extensive-stage small cell lung cancer failed to meet its co-primary endpoint of PFS.